Gapping up
In reaction to strong earnings/guidance: MCUR +10% (reports Q3 results and withdraws guidance given recently announced clinical trial results; commences a process to review all strategic alternatives ), DQ +6.1%, VIPS +4.2%, JACK +3.9%, LOW +2.1%, TGT +1.4%.
M&A news: FCS +8.7% (to be acquired by ON Semiconductor (ON) for $20/share in cash, or ~$2.4 bln), NSC +6.6% (Canadian Pacific proposes to acquire Norfolk Southern), CP +5.1% (Canadian Pacific proposes to acquire Norfolk Southern), AHS +3.5% (signs an agreement to acquire B.E. Smith for $160 mln in cash; expected to be immediately accretive to Co's GAAP and adjusted EPS), PSEM +3.2% (Montage Technology Group increases cash offer for Pericom Semiconductor Corporation to $19.00/share), CAG +2.9% (announces plans to separate into two independent public companies), PMCS +2.1% (Microsemi (MSCC) has increased its offer to acquire PMC-Sierra; new offer valued at $12.05/ PMCS share), .
Select Brazil related names showing strength: SID +15.2%, GGB +8.8%, EPR +2.6%, PBR +2.5%, BAK +2.2%, .
Select metals/mining stocks trading higher: VALE +3.2%, MT +3.1%, NEM +2.4%, RIO +1.7%, BBL +1.3%, BHP +1%, FCX +0.7%, .
Select oil/gas related names showing strength: SDRL +4.5%, RIG +2.1%, BP +1.7%, RDS.A +1.7%, TOT +1.6%, OAS +1.5% .
Other news: AVXL +27.5% (announces that it is moving forward with the development program for ANAVEX 2-73 in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial), MIFI +11.5% (announced that Wells Fargo Bank has increased the Company's five-year senior secured revolving credit facility to $48 million), UVE +8.7% (co issued a statement 'correct misleading allegations and misinformation presented by Lakewood Capital'), THLD +7.1% (enters into definitive co-promotion agreement for Evofosfamide w/ Merck KGaA (MKGAY)), DBVT +6.4% (presents preclinical Data on its Viaskin technology), DEPO +4.3% (acquired the rights to Cebranopadol from Grünenthal GmbH), RAX +4.1% (prices upsized offering of $500 mln of 6.500% senior notes due 2024), RDEN +3.6% (co's President of Global Fragrances, Joel B. Ronkin, resigned to accept a position as CEO of a privately-held personal care organization), COMM +2.1% (Maverick Capital's Lee Ainslie long recommendation), CSX +2% (on CP / NSC news), AXLL +1.7% (appointed Timothy Mann as CEO), STM +1.7% (semi peer), NVS +1% (Co's unit Sandoz receives FDA acceptance for proposed biosimilar pegfilgrastim), UNP+0.8% (on CP / NSC news).
Analyst comments: BLUE +4.6% (initiated with a Buy at Goldman), FARO +3.8% (upgraded to Buy from Hold at Canaccord Genuity), KITE +3.5% (initiated with a Buy at Goldman), TASR +3.3% (upgraded to Buy from Neutral at Ladenburg Thalmann), SBH +3.1% (upgraded to Buy from Neutral at Goldman), HALO +2.9% (initiated with a Buy at Citigroup), GPRE +2.8% (resumed with a Outperform at Credit Suisse), AAPL +1.6% (added to Conviction Buy List at Goldman), CGNX +1.5% (upgraded to Buy from Hold at Canaccord Genuity), MIDD +1.5% (upgraded to Outperform from Market Perform at BMO Capital Markets), INCY +1.3% (initiated with a Buy at Goldman
)
In reaction to strong earnings/guidance: MCUR +10% (reports Q3 results and withdraws guidance given recently announced clinical trial results; commences a process to review all strategic alternatives ), DQ +6.1%, VIPS +4.2%, JACK +3.9%, LOW +2.1%, TGT +1.4%.
M&A news: FCS +8.7% (to be acquired by ON Semiconductor (ON) for $20/share in cash, or ~$2.4 bln), NSC +6.6% (Canadian Pacific proposes to acquire Norfolk Southern), CP +5.1% (Canadian Pacific proposes to acquire Norfolk Southern), AHS +3.5% (signs an agreement to acquire B.E. Smith for $160 mln in cash; expected to be immediately accretive to Co's GAAP and adjusted EPS), PSEM +3.2% (Montage Technology Group increases cash offer for Pericom Semiconductor Corporation to $19.00/share), CAG +2.9% (announces plans to separate into two independent public companies), PMCS +2.1% (Microsemi (MSCC) has increased its offer to acquire PMC-Sierra; new offer valued at $12.05/ PMCS share), .
Select Brazil related names showing strength: SID +15.2%, GGB +8.8%, EPR +2.6%, PBR +2.5%, BAK +2.2%, .
Select metals/mining stocks trading higher: VALE +3.2%, MT +3.1%, NEM +2.4%, RIO +1.7%, BBL +1.3%, BHP +1%, FCX +0.7%, .
Select oil/gas related names showing strength: SDRL +4.5%, RIG +2.1%, BP +1.7%, RDS.A +1.7%, TOT +1.6%, OAS +1.5% .
Other news: AVXL +27.5% (announces that it is moving forward with the development program for ANAVEX 2-73 in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial), MIFI +11.5% (announced that Wells Fargo Bank has increased the Company's five-year senior secured revolving credit facility to $48 million), UVE +8.7% (co issued a statement 'correct misleading allegations and misinformation presented by Lakewood Capital'), THLD +7.1% (enters into definitive co-promotion agreement for Evofosfamide w/ Merck KGaA (MKGAY)), DBVT +6.4% (presents preclinical Data on its Viaskin technology), DEPO +4.3% (acquired the rights to Cebranopadol from Grünenthal GmbH), RAX +4.1% (prices upsized offering of $500 mln of 6.500% senior notes due 2024), RDEN +3.6% (co's President of Global Fragrances, Joel B. Ronkin, resigned to accept a position as CEO of a privately-held personal care organization), COMM +2.1% (Maverick Capital's Lee Ainslie long recommendation), CSX +2% (on CP / NSC news), AXLL +1.7% (appointed Timothy Mann as CEO), STM +1.7% (semi peer), NVS +1% (Co's unit Sandoz receives FDA acceptance for proposed biosimilar pegfilgrastim), UNP+0.8% (on CP / NSC news).
Analyst comments: BLUE +4.6% (initiated with a Buy at Goldman), FARO +3.8% (upgraded to Buy from Hold at Canaccord Genuity), KITE +3.5% (initiated with a Buy at Goldman), TASR +3.3% (upgraded to Buy from Neutral at Ladenburg Thalmann), SBH +3.1% (upgraded to Buy from Neutral at Goldman), HALO +2.9% (initiated with a Buy at Citigroup), GPRE +2.8% (resumed with a Outperform at Credit Suisse), AAPL +1.6% (added to Conviction Buy List at Goldman), CGNX +1.5% (upgraded to Buy from Hold at Canaccord Genuity), MIDD +1.5% (upgraded to Outperform from Market Perform at BMO Capital Markets), INCY +1.3% (initiated with a Buy at Goldman
)